In this study, we found a significant increase in both foveal contrast thresholds and vernier acuity thresholds in subjects with glaucoma. This confirms a number of previous studies that demonstrate abnormal foveal performance in glaucoma.
8 9 10 11 34 More specifically, our measurement of decreased foveal vernier acuity performance in subjects with glaucoma agrees with that reported by Piltz et al.
8 Generally, glaucoma is considered to be a condition that predominantly affects the peripheral visual field, in that foveal abnormalities are not usually found early in glaucoma by using perimetric paradigms. This is supported in the present study by the finding of no significant correlations between vernier acuity performance and the global indices produced by the visual field analyzer in our patients with glaucoma. It has been argued that this may be due, in part, to the logarithmic scale used to measure luminance increment sensitivity in glaucoma, because many more ganglion cells must be lost foveally than peripherally to detect a 3-dB loss of visual field sensitivity.
35
It is well documented that vernier acuity thresholds decrease with increasing stimulus contrast according to a power law.
12 13 14 15 16 17 Because of the dependence of vernier acuity on contrast, deficits in vernier performance may manifest in disease simply because of reduced contrast sensitivity rather than a reduction in vernier acuity per se. When achromatic targets of normalized contrast were used, a difference in contrast sensitivity between the groups was still found, however, indicating a genuine loss of foveal vernier acuity in glaucomatous observers. That this loss was not statistically demonstrated with the 90% contrast achromatic targets (
Fig. 2 , left) is probably due to the poor power of the
t-test performed, in comparison with the ANOVA analysis
(Fig. 4) . This difference in power is most directly attributable to the fourfold increase in data used in the ANOVA. One plausible explanation for the significant decrease in vernier acuity is that it represents a disruption of spatial sampling, due to ganglion cell loss. Because of this, it may be expected that vernier performance is correlated with contrast sensitivity losses resulting from ganglion cell loss. No correlation was found between vernier acuity and depth of visual field defect, however, as assessed by standard perimetric indices
(Fig. 5) . This noncorrelation may, in part, reflect that standard perimetric indices are weighted by performance in the peripheral visual field, whereas vernier acuity is dependent on function in the central visual field. However, we also found losses in vernier acuity that were independent of central losses in contrast sensitivity
(Fig. 4) . As such, vernier acuity deficits may occur in some patients with glaucoma despite the presence of normal contrast sensitivity.
We did not find evidence for a more rapid decrease in vernier acuity performance with reducing contrast in glaucoma, when compared with that in control subjects. This is illustrated by the similar shapes of the curves in
Figure 4 , as well as the absence of a significant interaction between contrast and subject group in the ANOVA analysis of the data represented in
Figure 4 . When the thresholds at each contrast level were considered separately, the glaucoma group performed significantly worse than the control group at eight times contrast threshold. No significant difference was found at the other contrast levels. It is possible that, at low contrast, both groups had more difficulty with the task, resulting in a reduction in the ability to distinguish between the groups. However, the spread of the data at four times contrast threshold does not demonstrate relatively increased variability. Nevertheless, it is possible that testing at intermediate contrast may provide some advantage over testing at high contrast for the purpose of distinguishing between individuals with glaucoma and those with normal vision. In particular, larger differences are expected to be manifest between the groups when they are tested at the same absolute contrast level (rather than equivalent contrast), because the glaucoma group should demonstrate a reduction in vernier threshold due both to their reduced contrast sensitivity and to a genuine reduction in vernier performance.
Similar to the findings of Piltz et al.,
8 we found considerable overlap between the vernier thresholds of normal control subjects and patients with glaucoma when measured with static achromatic stimuli. Differences between the groups were more marked when visual-function–specific stimuli (short-wavelength spots and frequency-doubling gratings) were used. The nature of our short-wavelength stimulus necessitates its detection by short-wavelength–sensitive mechanisms, which are known to be affected early in glaucoma.
19 20 21 The frequency-doubling grating vernier task used in this study is likely to be detected by magnocellular mechanisms, which are also known to be affected in glaucoma.
23 24 36 37 It is unclear whether magnocellular or parvocellular pathways mediate the detection of static achromatic vernier tasks
38 39 40 ; however, it seems likely that the magnocellular pathway is primarily involved at low contrast.
40 Although thresholds on the two visual-function–specific tasks investigated were elevated beyond what is generally considered to be hyperacuity in both normal and glaucomatous observers, these stimuli may have advantages for the detection of spatial sampling changes due to retinal ganglion cell loss, because the neural pathways responsible for their detection are sparsely represented. It should be noted, however, that patients with glaucoma are likely to have reduced contrast sensitivity for both the short-wavelength and frequency-doubling grating tasks. We did not equilibrate contrast between the control and glaucoma groups for the assessment of short-wavelength and frequency-doubling grating vernier acuity and therefore do not know how much of the difference between the groups can be explained by differential contrast sensitivity.
Although further validation of the utility of vernier acuity or other similar hyperacuity measures to detect glaucomatous visual dysfunction is needed, these measures may provide an indirect measure of ganglion cell sampling and may have the potential to reveal dysfunction before traditional visual field assessment.